Actively Recruiting
Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus
Led by Glaukos Corporation · Updated on 2026-02-10
100
Participants Needed
1
Research Sites
66 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Multi-center, parallel-group, placebo-controlled trial designed to assess the safety and efficacy of twice-daily topically administered GLK-221 Ophthalmic Solution in subjects with keratoconus.
CONDITIONS
Official Title
Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Be 18 years or older and 55 years or younger
- Have a diagnosis of keratoconus in the study eye
You will not qualify if you...
- Are pregnant, lactating, or planning a pregnancy
- Are currently enrolled or were enrolled within 30 days prior to screening in another investigational drug or device trial
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Glaukos Clinical Study Site
Westerville, Ohio, United States, 43082
Actively Recruiting
Research Team
S
Study Manager
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here